학술논문
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
Document Type
Article
Author
Zielinski, Christoph; Láng, István; Inbar, Moshe; Kahán, Zsuzsanna; Greil, Richard; Beslija, Semir; Stemmer, Salomon M; Zvirbule, Zanete; Steger, Günther G; Melichar, Bohuslav; Pienkowski, Tadeusz; Sirbu, Daniela; Petruzelka, Luboš; Eniu, Alexandru; Nisenbaum, Bella; Dank, Magdalena; Anghel, Rodica; Messinger, Diethelm; Brodowicz, Thomas
Source
In The Lancet Oncology September 2016 17(9):1230-1239
Subject
Language
ISSN
1470-2045